Qsymia is a branded pharmaceutical product indicated for weight management. It combines phentermine and topiramate as active ingredients. The product was launched in Korea, reflecting its availability in regulated pharmaceutical markets. This type of combination therapy is commonly used in medical weight loss programs, often prescribed alongside lifestyle modifications for patients with obesity or weight-related comorbidities.
Lotus Pharmaceutical, based in Tashkent, Uzbekistan, manufactures this product. The company was founded in 1966, establishing a long operational history in the pharmaceutical sector. As a manufacturer in the Pharmaceutical Products category, Lotus Pharmaceutical supplies Qsymia to international sourcing buyers seeking branded weight management solutions. The product is positioned for buyers requiring clinically-developed therapeutics for distribution in markets where it is registered and approved.